Nanobiotix Completes Dose Escalation Portion of Phase 1 Study Targeting Non-Small Cell Lung Cancer -April 2, 2024 at 11:23 PM

Nanobiotix Completes Dose Escalation Portion of Phase 1 Study Targeting Non-Small Cell Lung Cancer -April 2, 2024 at 11:23 PM
Nanobiotix Completes Dose Escalation Portion of Phase 1 Study Targeting Non-Small Cell Lung Cancer -April 2, 2024 at 11:23 PM
--

Nanobiotix is ​​a pioneer and market leader in the field of nanomedicine, thanks to a revolutionary approach to cancer treatment. The company focuses its efforts on developing its portfolio of patented products, NanoXray, an innovation based on the physical action of nanoparticles that, through the action of radiotherapy, optimize the absorption of X-rays in cancer cells without damaging the surrounding healthy tissues receive increasing doses. NanoXray products are compatible with standard radiotherapy treatments and are aimed at potentially treating many different types of cancer through numerous routes of administration. The Company’s resources are primarily focused on the development of its lead product candidate NBTXR3, which is the product of its proprietary oncology platform and has already received marketing authorization in Europe for the treatment of patients with branded soft tissue sarcoma Hensify®.

Learn more about the company

The article is in Dutch

Tags: Nanobiotix Completes Dose Escalation Portion Phase Study Targeting NonSmall Cell Lung Cancer April

-

PREV First Tellurium Corp. Reports results for the second quarter and six months ended January 31, 2024 -April 3, 2024 at 12:06 AM
NEXT Record-breaking faint and light companion to the Milky Way discovered (which may be packed with dark matter)